Cite
HARVARD Citation
Mougalian, S. et al. (n.d.). 167PUtilization and outcomes of Eribulin Mesylate POst a cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i): An observational real-World study in UnitEd States community oncology pRactices (EMPOWER). Annals of oncology. p. . [Online].